Christos Sotiriou

Translational Research Unit, Jules Bordet Institute, Belgium

Dr. Christos Sotiriou earned a medical degree from the Universit� Libre de Bruxelles, Belgium, in 1993. He did his internal medicine/oncology residency at the Jules Bordet Institute (Profs. J. Klastersky, M. Piccart), and he earned his specialty in internal medicine and medical oncology in July 1999 at the Universit� Libre de Bruxelles. During his last year of residency, he worked as research fellow at the Laboratory of Endocrinology, Bone Metabolism and Breast Oncology (Dr J. Body), at the Jules Bordet Institute, supported by an educational grant from the Belgian National Foundation of Scientific Research.

From October 1999 till September 2001, he worked as basic research fellow, at the Division of Clinical Sciences, Microarray Facility, National Cancer Institute (Pr Edison Liu), National Institutes of Health, Bethesda, MD, USA, supported by an educational grant from the Association "Yvonne et Thomas Rucquois - Les Amis de l'Institut Jules Bordet - Belgium", and the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. During his fellowship he received a Scholar in Training Award for the study of the expression profiling analysis of von Hippel-Lindau tumor suppressor gene from the American Association for Cancer Research, March 24-28, 2001, New Orleans, USA. Since October 2001, he has been Assistant Professor at the Medical Oncology Clinic of the Jules Bordet Institute.

Dr. Sotiriou earned his doctor of philosophy degree (PhD) from the Université Libre de Bruxelles, Belgium in September 2004. He was promoted Head of the Functional Genomics and Translational Research Unit of the Jules Bordet Institute in October 2004 and, in October 2005 he will become a research associate at the Belgian National Foundation of Scientific Research (FNRS). Dr. Sotiriou's research focuses on genomics and molecular biology in breast cancer.

Dr. Sotiriou is a member of ASCO, AACR, and ESMO and also member of the Steering and Executive committee of TRANSBIG, a "sister" network of the Breast International Group (BIG aisbl), dedicated multinational translational research linked to prospective clinical trials, since 2003. He presently has several publications in peer review journals and three book chapters. He is also a reviewer for several scientific journals. He received several educational and research grants from the Swiss Foundation MEDIC, the National Foundation of Cancer Research, the Université Libre de Bruxelles, the "Fonds Jean-Claude Heuson", the Fondation Lambeau-Marteau, the Belgian Federation against Cancer, and the European Union Framework VI Programme.

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Oncology > Breast Diseases: Benign & Malignant (since 28 April 2006)

Links

http://www.bcrfcure.org/action_0708grantees_sotiriou.html

All recent recommendations

• 6.0
  Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
  Recommended by Christos Sotiriou with Michail Ignatiadis
  
• 4.8
  Isolation of rare circulating tumour cells in cancer patients by microchip technology.
  Recommended by Gene LeSage with Xuefeng Xia, Christos Sotiriou with Michail Ignatiadis
  
• 3.0
  Molecular response to aromatase inhibitor treatment in primary breast cancer.
  Recommended by Christos Sotiriou